NAD+
The base layer of those who endure.
- Sizes available
- 50mg · 100mg · 250mg · 500mg
- Lab certificate (COA)
- Supplier-published sample
· Research-grade only · Not for human consumption · 21+ ·
NAD+. Cellular energy and sirtuin activation. Core longevity cofactor.
Mechanism · Nicotinamide Adenine Dinucleotide. Sirtuin cofactor + DNA repair (PARP).
Best for. Not for.
Best for
- Core longevity cofactor (Sinclair Harvard research)
- Energy / cellular function decline users who experienced (40+)
- IV NAD+ protocol or subcutaneous use
Not for
- Active malignancy or cancer history (PARP cofactor. Proliferation concern)
- Pregnancy or nursing
- Rapid IV push (flush / racing heart)
- NMN FDA NDI rejection 2022. Supplement classification unclear
Mechanism, dose, ramp, risk.
- Mechanism
- Nicotinamide adenine dinucleotide. Cofactor for sirtuin activity and DNA repair.Source · PEPVERA editorial
- Target dose
- 100 mg / day subq, or 500 mg / week IV-supervised.Source · PEPVERA editorial
- Ramp
- Begin at 25 mg. Ramp to tolerance.Source · PEPVERA editorial
- Risks
- Flush, racing heart on rapid push.Source · PEPVERA editorial
Compared to its siblings.
NAD+
NAD+. Cellular energy and sirtuin activation. Core longevity cofactor.
Pros
- · Broad commercial brand availability (Niagen, Basis) absent in MOTS-c.
- · No missed Phase 3 primary endpoint like SS-31's MMPOWER-3.
Cons
- · Cytosolic mechanism, not targeted mitochondrial like MOTS-c.
- · No Phase 3 clinical pipeline like SS-31's Stealth trials.
MOTS-c
Mitochondrial peptide. Exercise mimetic.
Pros
- · Targeted mitochondrial
Cons
- · Pre-clinical
See MOTS-c →
SS-31 (elamipretide)
Mitochondrial-targeted antioxidant (elamipretide).
Pros
- · Stealth Phase 3 trials
Cons
- · MMPOWER-3 primary endpoint missed 2021
See SS-31 (elamipretide) →
COA per supplier
Published, in-house, or shipment-time
Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.
Compare 10 suppliers
| Supplier | Price | COA | Ships | |
|---|---|---|---|---|
| Pure Peptide UKUK | $40$0.08/mg · 500mg | In-house COA | 4 days | Out of stock |
| Ameano PeptidesUS | $44$0.18/mg · 250mg | Sample COA published | 2 days | |
| SwissChemsUS | $47.95$0.48/mg · 100mg | COA with shipment | 3 days | |
| NG PeptidesUS | $50$0.10/mg · 500mg | Sample COA published | 3 days | Out of stock |
| Ascension PeptidesUS | $58$0.12/mg · 500mg | Sample COA published | 3 days | Out of stock |
| PeptiraUS | $59$0.12/mg · 500mg | COA with shipment | 3 days | Out of stock |
| Orion PeptidesUS | $64.99$0.13/mg · 500mg | COA with shipment | 3 days | Out of stock |
| Royal PeptidesUS | $65$0.13/mg · 500mg | Sample COA published | 3 days | |
| Ameano PeptidesUS | $68$0.14/mg · 500mg | Sample COA published | 2 days | |
| NG PeptidesUS | $135$2.70/mg · 50mg | Sample COA published | 3 days | Out of stock |
Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.
Week 1–2
100 mg / day subq, or 500 mg / week IV-supervised.
Initiation
Week 3–4
100 mg / day subq, or 500 mg / week IV-supervised.
Signal emerges
Week 5–8
100 mg / day subq, or 500 mg / week IV-supervised.
Hold
Week 9–12
Cycle review
Assess
Draw 8 units.
10 mg = 0.08 mL at 125.00 mg/mL. 25.0 doses per vial.
eternal · II · Ameano Peptides
NAD+ · 250mg